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InternationalBackground: A subset of patients with phenylketonuria benefit from treatment with tetrahydrobiopterin (BH4),
although there is no consensus on the definition of BH4 responsiveness. The aim of this study therefore was to
gain insight into the definitions of long-term BH4 responsiveness being used around the world.
Methods:Weperformed aweb-based survey targeting healthcare professionals involved in the treatment of PKU
patients. Data were analysed according to geographical region (Europe, USA/Canada, other).
Results:Weanalysed 166 responses. Long-termBH4 responsivenesswas commonly defined using natural protein
tolerance (95.6%), improvement of metabolic control (73.5%) and increase in quality of life (48.2%).When a spe-
cific value for a reduction in phenylalanine concentrations was reported (n = 89), 30% and 20% were most fre-
quently used as cut-off values (76% and 19% of respondents, respectively). When a specific relative increase in
natural protein tolerance was used to define long-term BH4 responsiveness (n = 71), respondents most com-
monly reported cut-off values of 30% and 100% (28% of respondents in both cases). Respondents from USA/
Canada (n = 50) generally used less strict cut-off values compared to Europe (n = 96). Furthermore, respon-
dents working within the same center answered differently.
Conclusion: The results of this study suggest a very heterogeneous situation on the topic of defining long-term
BH4 responsiveness, not only at a worldwide level but also within centers. Developing a strong evidence- and
consensus-based definition would improve the quality of BH4 treatment.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).alanine hydroxylase; Phe, phenylalanine; PKU, phenylketonuria; USA, United States of America.
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Phenylketonuria (PKU, MIM 261600) is an inborn error of amino
acid metabolism caused by a deficiency of the enzyme phenylalanine
(Phe) hydroxylase (PAH) [1]. If left untreated, PKU causes high blood
Phe concentrations, leading to severe intellectual disability and behav-
ioural problems. Therefore, limitingdietary Phe intake through a natural
protein-restricted diet is essential. Together with the intake of amino
acid supplements, this life-long treatment is effective in preventing
most complications associated with untreated PKU. However, the treat-
ment for PKU may pose a high burden for patients and caregivers, and
can be hard to maintain, especially after childhood [2]. Moreover, out-
come in some treated PKU patients is still suboptimal [3].
Besides the dietary treatment, the pharmacological chaperone
tetrahydrobiopterin (BH4) is beneficial for a subset of PKU patients. In
BH4-responsive patients, treatment with BH4 increases residual PAH ac-
tivity, which results in a decrease in blood Phe concentrations and/or an
increase in natural protein tolerance [4]. Considering not all PKU patients
respond to BH4, it is important to appropriately select patients with PKU
who benefit from long-term BH4 treatment. Evaluating eligibility for
treatment with BH4 is typically done by performing a BH4 testing period
or treatment trial to assess its effects. However, there is on-going debate
on how BH4 responsiveness should be defined, i.e. which effects of BH4
treatment justify long-term treatment. This debate is also reflected by dif-
ferences in the recommendations in the two major international PKU
guidelines [5,6]. Specifically, the European guidelines define BH4 respon-
siveness as an increase of 100%ormore in natural protein tolerance or im-
proved biochemical control (>75% of phenylalanine levels in target
range), whereas the American guidelines state that clinical judgement is
required to determine BH4 responsiveness.
To harmonize treatment for PKU patients and ensure appropriate
use of BH4, it is important to have a uniform definition of BH4 respon-
siveness that can be used by healthcare professionalsworldwide. There-
fore, it is necessary to have a good overview of the definitions of BH4
responsiveness that are currently used, and to assess the extent of
agreement on this topic. We therefore performed an international sur-
vey among healthcare professionals working in the field of PKU.
2. Methods
2.1. General information
We performed a survey using a web-based questionnaire targeting
healthcare professionals involved in the care of PKU patients. The med-
ical ethical committee of the University Medical Center Groningen
ascertained that our study protocol was not clinical research with test
subjects as meant in the Dutch Medical Research act involving human
subjects, and therefore did not find it necessary to review the protocol.
The CHERRIES checklist for reporting results of internet e-surveys was
used to draft this manuscript [7]. Compliance with this checklist is de-
scribed in Supplementary material 1, where additional methodological
information can be found as well.
2.2. Questionnaire development
A first draft of the questionnaire was developed by RAFE, AMJvW
and FJvS. All other authors were given the opportunity to comment on
this version. With these comments a second version of the question-
naire was developed, which was used for this survey (Supplementary
material 2). Adaptive questioning was implemented to present specific
follow-up questions depending on previous answers. Consequently, re-
spondents who indicated that their centre did not use BH4 as a treat-
ment option for PKU patients received no questions concerning their
definition of BH4 responsiveness. The survey contained, depending on
the responses, between 4 and 19 closed, semi-closed and open ques-
tions. Qualtrics (https://www.qualtrics.com/)wasused to record survey2
responses. The technical functionality was tested by RAFE and AMJvW.
The survey was available in English only.
2.3. Questionnaire distribution
The surveywas open to everyonewith access to the anonymous sur-
vey link. This link was distributed per email to healthcare professionals
involved with PKU patients via the Metab-L and SSIEM mailing lists. In
the invitation email, the goal of the study as well as the approximate
time it would take to complete the survey was mentioned. A reminder
was sent two weeks after the first invitation. After five more weeks, a
second reminder was sent, specifically targeting SSIEM members from
countries from which no response had yet been received. All invitees
were encouraged to forward the invitation email to colleagues. Data
were collected from March 8 to May 23, 2019.
2.4. Data analysis
Only complete questionnaires were analysed. IP addresses, location
data (latitude and longitude), survey starting dates and times, and re-
spondent names and main functions were checked to control for multi-
ple entries from the same individual. Multiple responses per center
were allowed because entries from different healthcare professionals
working in the same center sometimes gavemarkedly different answers
to the questionnaire. Since some answers to open questions covering
the same subtopic overlapped, we analysed the overall survey results
per subtopic and not per specific question. The following additional
measures that were taken to enable analysis of the dataset: [1] if a re-
spondent gave the same answer multiple times in different open ques-
tions, redundant answers were removed; [2] if a respondent gave a
range for a cut-off value, the lowest number in that range was used;
[3] answers regarding dietary intake given as mg Phe were converted
into grams natural protein (using a conversion factor of 50 mg Phe for
1 g of natural protein); [4] sincewe aimed to analyse general healthcare
practices, answers thatwere related to specific caseswere not analysed;
[5] answers that were unrelated to defining BH4 responsiveness were
removed; [6] responses to open questions were grouped.
Data were analysed using descriptive statistics and grouped accord-
ing to geographical region (total, Europe, the United States of America
(USA)/Canada). Differences between Europe and USA/Canada were
assessed using Fisher's exact test, and cut-off values were considered
as ordinal variables. IBS SPSS was used for all analyses.
3. Results
3.1. Responses
Three-hundred and forty different visitors clicked on the link in the
invitation email, of whom 326 completed the first page of the survey
(participation rate of 95.9%). Two-hundred and seventeen participants
completed the entire questionnaire (completion rate of 66.6%).
3.2. Participants
Of the 217 respondents who completed the questionnaire, 50 re-
spondents indicated that their center did not use BH4 treatment.
These responses came from Chile, Costa Rica, the Czech Republic,
Finland, Ireland, Japan, Lebanon, Moldova, the Netherlands,
Philippines, Serbia, Sri Lanka and Sweden (all n = 1); Croatia, France,
Iran, Pakistan, Poland and Spain (all n = 2); Australia, Greece and USA
(all n = 3); and the United Kingdom (n = 16). These responses were
not used in further analyses. Additionally, one response was excluded
from the analyses since it did not provide clear information.
Of the 166 remaining responses from 38 countries, 96 responses
came from Europe (22 countries), 50 responses from USA/Canada
(two countries), and 20 responses from other parts of the world (14
Table 2










10% 6% 4% 11% 0%
15% 1% 0% 6% 0%
20% 11% 7% 6% 50%
25% 3% 0% 11% 0%
30% 28% 20% 61% 0%
40% 4% 4% 0% 13%
50% 15% 18% 6% 25%
70% 1% 2% 0% 0%
100% 28% 42% 0% 13%
150% 1% 2% 0% 0%
Table 3
Cut-off values for a decrease in phenylalanine concentrations that respondents used to









20% 19% 10% 26% 33%
25% 2% 5% 0% 0%
30% 76% 86% 71% 56%
50% 2% 0% 3% 11%
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sponse from 26 centres (Supplementary material 3). Almost all respon-
dents were either a physician (67.1%) or a dietician (25.7%). The
distribution of physicians and dieticians differed in Europe compared
to USA/Canada: in Europe, 81% of respondents were physicians, and
14% were dieticians; in USA/Canada, 40% were physicians, and 52%
were dieticians.
3.3. Definitions of long-term BH4 responsiveness
Table 1 shows the main criteria respondents used for defining
long-term BH4 responsiveness. Almost all respondents indicated using
an increase in natural protein tolerance to define long-termBH4 respon-
siveness, although improvement of metabolic control and increase in
quality of life were also commonly used. The use of other criteria in-
cluded neurocognitive and neurodevelopmental improvement.
For an increase in natural protein tolerance (n = 157, Supplemen-
tary materials 4), most respondents (52.2%) used a relative increase in
natural protein tolerance to define long-term BH4 responsiveness.
When respondents used a specific cut-off value for this criterion, cut-
off values of 30% and 100% were most often used, followed by 50% and
20% (Table 2).When respondents used a specific cut-off value for an ab-
solute increase in natural protein tolerancemeasured in grams (28.0%),
the most common cut-off value was 5 g (range: 0.2 to 20 g). When re-
spondents used a specific cut-off value for an absolute increase in natu-
ral protein tolerance per kilograms bodyweight (13.4%), the most
common cut-off value was 0.5 g per kilogram (range: 0.05–30 g per
kg). Furthermore, most respondents (75.6%) stated that as long as
blood Phe concentrations stay within target range, any increase in Phe
concentrations is allowed when increasing natural protein intake.
For an improvement in metabolic control (n= 122, Supplementary
materials 5), most respondents (73.0%) indicated that patients must
show a specific reduction in Phe concentrations to be considered as
long-term BH4 responsive. The cut-off value of 30% was most often
used, but the use of 20% as cut-off value was not uncommon (Table 3).
Alternatively, respondents defined long-term BH4 responsiveness
using the target range of blood Phe concentrations (51.6%), mostly re-
quiring a specific percentage of Phe concentrations to bewithin the tar-
get range. The most common cut-off values for this were 75%, 70%
and 80%.
Regarding respondents who used an increase in quality of life to de-
fine BH4 responsiveness (n = 80, Supplementary materials 6), only a
small proportion measured quality of life using questionnaires (11%).
For most respondents, the increase in quality of life was judged by the
patients and/or family/parents (91%) and/or by (someone of) the
patient's healthcare team (36%).
3.4. Differences between Europe and USA/Canada
Several differences were found between respondents from Europe
versus USA/Canada. Improvement of metabolic control and increase in
quality of life were significantly more often used in USA/Canada to de-
fine long-term BH4 responsiveness (p < 0.001 and p = 0.02, respec-
tively). Respondents from USA/Canada more often used stable PheTable 1
Main criteria respondents used to define long-term BH4 responsiveness. Compar
Main criterion Total
(n = 166)
Improvement of metabolic control 73.5%
Increase in natural protein tolerance 94.6%
Increase in quality of life 48.2%
Other 3.6%
*p < 0.05; *** p < 0.001.
3
concentrations (p=0.01) and tended tomore commonly use a specific
reduction in Phe concentrations (p = 0.09) to define BH4 responsive-
ness compared to responders from Europe. The cut-off values for a spe-
cific percentage reduction in Phe concentrations differed (p = 0.04),
with Europe using more strict cut-off values. This was also the case for
the cut-off values for a relative increase in natural protein tolerance
(p < 0.001). Separate analyses for physicians and dieticians, revealed
an overall similar picture (Supplementary material 7), although many
differences between Europe and USA/Canadawere no longer significant
in these smaller subgroups.3.5. Differences within centres
To gain a general impression of the consensus on defining BH4 re-
sponsiveness within the 26 centres from which we received more
than one response, we investigated three aspects: [1] the use of general
criteria (such as metabolic control, natural protein tolerance, and qual-
ity of life); [2] the use of a cut-off value (%) for a decrease in Phe concen-
trations; and [3] the use of a cut-off value (%) for a relative increase in
natural protein tolerance. We found that within 21 of the 26 centres,
not all respondents used the same general criteria to assess BH4 respon-
siveness. Furthermore, in 11 centres some but not all respondents used
a specific percentage decrease in Phe concentrations to define BH4 re-
sponsiveness, and in four centres different cut-off values were used by
different healthcare professionalsworkingwithin the same centre. Sim-
ilarly, in six centres, some but not all respondents used a specific cut-off
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working within the same centre. Differences within centers were ob-
served both within the same profession (among physicians and
among dieticians) and between different professions.
3.6. Confidence and guidelines
Most respondents indicated they felt ‘very confident’ (18.1%) or
‘somewhat confident’ (65.1%) about the definition(s) of BH4 respon-
siveness they use, and only 16.9% of respondents felt ‘not so confident’.
Nevertheless, the majority of participants responded that they would
‘definitely’ (48.8%) or ‘probably’ (31.9%) be helped by a guideline that
gives a better definition. However, 13.9% indicated that they ‘might or
might not’ be helped, and 4.2% and 1.2% said they would ‘probably’ or
‘definitely’ not be helped by such a guideline.
4. Discussion
With this study, we aimed to get a better picture of the definitions of
long-term BH4 responsiveness that are usedworldwide. Ourmain find-
ing is the overall lack of consensus regarding this topic among
healthcare professionals. This is evident at a worldwide level, but also
on a regional level (within Europe and USA/Canada), and even within
centres. Despite these large differences, healthcare professionals are re-
markably confident about their own definition of long-term BH4 re-
sponsiveness, although, conversely, most stated that they would be
helped by a guideline that gives a better definition.
Firstly, wewill discuss the strengths and limitations of our study. The
main strength is the large number of respondents. As opposed to several
recent practice surveys for PKU [8–12], we did not focus on a specific
country or region. As a result, we received responses frommany differ-
ent countries around the world, making this the largest practice survey
reported about PKU. We especially received many responses from
Europe and USA/Canada, enabling us to investigate certain differences
between these regions. The limitations of this study are largely related
to the general limitations of performing a survey. Firstly, both questions
and answers (to open-ended questions) may have been wrongly
interpreted. Specifically, some of the reported cut-off values for an abso-
lute increase in natural protein tolerance per kilograms bodyweight
seemed extremely unrealistic (e.g. a cut-off value of 30 g per kilogram
bodyweight). Furthermore, a selection bias is certainly present, with re-
spect to both the individual respondents and the countries from which
we received responses. However, due to the large number of respon-
dents, we estimate that these limitations do not have a large influence
on the main conclusions of this study.
It is clear that little agreement exists on the definition of long-term
BH4 responsiveness. Applying the often-used arbitrary cut-off value of
70% to define consensus in the total group of respondents, consensus
only exists for the use ofmetabolic control and natural protein tolerance
as criteria for defining long-term BH4 responsiveness. Specific aspects,
such as cut-off values, were all used by less than 70% of the total
group of respondents. Moreover, our results show large differences be-
tween healthcare professionals whoworkwithin the same centre. Illus-
trative for the lack of consensus was the use of quality of life: around
half of the respondents used this criterion to define long-term BH4 re-
sponsiveness. These findings are in contrast with the general feeling of
confidence that the respondents had regarding their own definition of
BH4 responsiveness. Ironically, with over 83% of respondents answering
that they felt somewhat to very confident, few other questions in our
survey were answered with a similarly high level of agreement.
This survey also shows that the definition of BH4 responsiveness
from the 2017 European guidelines for PKU have not yet been imple-
mented in all European countries [13]. These guidelines define BH4 re-
sponsiveness as an increase of 100% or more in natural protein
tolerance or improved biochemical control (>75% of phenylalanine
levels in target range). Only 20% of the European respondents used4
the first part of this definition, and an even smaller proportion (5%)
used the second part. As stressed previously [14], more insights into
the adherence to the European PKU guidelines is needed, and reasons
for lack of adherence (e.g. lack of awareness or disagreement) should
be investigated. Moreover, our findings indicate the need of an imple-
mentation trajectory to improve the application of guidelines [15].
Comparisons between Europe and USA/Canada showed some signif-
icant differences. Perhapsmost interesting are the differences regarding
cut-off values, indicating that professionals in USA/Canada generally use
less strict cut-off values. Although the cause of this is not clear, it may be
related to the PKU guidelines from the American College of Medical Ge-
netics and Genomics, which were published in 2014 [5]. These guide-
lines do not give a specific definition of BH4 responsiveness, leaving it
to the clinician to judge which precise effects are significant and thus
define BH4 responsiveness. This freedompossibly leads to the use of rel-
atively low cut-off values and, more or less by definition, results in a
more heterogeneous situation.
Reaching more consensus on this subject would be preferable for
multiple reasons. Firstly, this would lead to equality in access to BH4
treatment regardless of the country or center in which the patient is
treated, or the healthcare professional by whom the patient is treated.
Secondly, it promotes cost-effective treatment, avoiding unnecessary
prescription of this expensive treatment to those who do not benefit.
Thirdly, reaching more consensus would facilitate the development of
an optimal testing regime for BH4 responsiveness, since the effective-
ness of such a regime depends on the definition [16]. Lastly, reaching
consensus on the definition of BH4 responsiveness may serve as a
framework for defining effectiveness of new PKU treatment modalities
that could partly or wholly replace dietary treatment. This includes
pharmacological treatment with pegvaliase, especially since recently
published recommendations on this treatment state that ‘clinically
meaningful efficacy benefit should be determined by the treating clini-
cian’ [17], similar to the American recommendations for BH4 treatment.
Althoughmost respondents answered they felt confident about their
definition of BH4 responsiveness, a majority also indicated that they
would behelpedwith a guideline that gives a better definition of BH4 re-
sponsiveness. Ideally, such a definition of BH4 responsiveness should be
evidence-based. To this end, firstly, the evidence on long-term effects of
BH4 treatment needs to be reviewed. While it is known that BH4 treat-
ment can decrease Phe concentrations and increase natural protein tol-
erance [18], it is unclear how changes in these parameters are related to
secondary outcomes, such as quality of life, neurocognitive functioning,
nutritional status, and anthropomorphic measures. A systematic review
on this topic could give valuable insights into the long-term benefits of
BH4 treatment and how these benefits relate to the level of BH4 respon-
siveness. While it is likely that the currently available evidence is not
sufficient to provide clear-cut answers, such a review would serve as a
solid basis to develop an evidence- and consensus-based definition of
long-term BH4 responsiveness. Furthermore, it is also crucial that a
new definition of BH4 responsiveness is useful in daily practice. To
that aim, the outcomes of this survey, reporting on a large variety of def-
initions of BH4 responsiveness that are currently used, may be of help.
5. Conclusion
The results of this large worldwide practice survey show a very het-
erogeneous picture regarding the definition of BH4 responsiveness that
healthcare professionals use in daily practice. Considering the implica-
tions of the large differences in definitions of BH4 responsiveness that
were observed, even within centres, it is clear that an evidence- and
consensus-based definition of long-term BH4 responsiveness should
be developed to improve the quality of BH4 treatment in PKU patients.
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